"[Latar Belakang : Sesak napas merupakan keluhan utama pada kanker paru. Obat
golongan opioid seperti morfin dapat digunakan untuk mengurangi keluhan sesak
napas. Penelitian ini bertujuan untuk menetapkan efek pengurangan sesak napas
dengan pemberian morfin oral lepas lambat 2x10 mg dan 2x30 mg, serta efek
samping yang ditimbulkan.
Metode : Penelitian uji klinis dengan subjek pasien kanker paru dengan
membandingkan keluhan sesak napas sebelum dan sesudah pemberian morfin oral
2x10 mg selama 2 hari dan dilanjutkan dengan 2x30 mg selama 2 hari. Derajat
sesak dinilai dengan menggunakan skor sesak modified Borg?s dyspnea scale dan
Visual Analog Scale (VAS) untuk sesak. Efek samping dipantau selama
pemberian obat.
Hasil : Tiga puluh tiga peserta penelitian dengan 27 laki-laki (81,8%), jenis
kanker paru adenokarsinoma 25 orang (75,8%). Terdapat perbaikan keluhan sesak
napas setelah morfin 2x10 mg pada 18 dari 33 peserta (54,5%) dengan penurunan
rata-rata skor sesak Borg dan VAS sebanyak 0,70 dan 6,72 dengan p <0,001
dibanding skor awal. Setelah pemberian morfin 2x30 mg perbaikan sesak napas
didapat pada 26 dari 33 peserta (78,8%) dengan penurunan rata-rata skor sesak
Borg dan VAS sebanyak 1,64 dan 16,06 dengan p <0,001 dibanding skor awal.
Terdapat perbedaan bermakna antara pemberian morfin 2x10 mg dan 2x30 mg (p
<0,001). Efek samping yang didapat setelah morfin 2x30 mg yaitu 33,3%
mengeluh konstipasi, 42,4% mengantuk, dan 12,1% mual. Tidak ada pasien yang
mengalami depresi pernapasan berat.
Kesimpulan : Terdapat perbaikan keluhan sesak napas setelah pemberian morfin
oral lepas lambat 2x10 mg dan dan perbaikan yang lebih baik dengan 2x30 mg. Tidak ada efek samping yang berat setelah pemberian morfin oral.;Background: Dyspnea is a major complaint in lung cancer. Opioids drugs such as
morphine is known to be used to reduce dyspnea. This study aims to determine
whether there is an improvement of dyspnea by titrating morphine sustained
release tablet 2x10 mg and 2x30 mg in lung cancer patient, and the side effects
that appear.
Methods: The study is a clinical trial with the subject of lung cancer patients by
comparing dyspnea before and after administration of 2x10 mg morphine tablets
for 2 days, followed by 2x30 mg for 2 days. The degree of dyspnea assessed using
the modified Borg's dyspnea scale and the Visual Analog Scale (VAS) for
dyspnea. Side effects are observed during administration of the drug.
Results: Thirty-three study participants with predominantly 27 men (81.8%) and
25 participants with adenocarcinoma (75.8%). There were improvements in
dyspnea after morphine 2x10 mg in 18 of the 33 participants (54.5%) with an
average improvements of Borg and VAS scores for 0.70 and 6.72 with p <0.001
compared to the initial score. After administration of morphine 2x30 mg
improvements in dyspnea were obtained in 26 of the 33 participants (78.8%) with
an average improvements of Borg and VAS scores for 1.64 and 16.06 with p
<0.001 compared to the initial score. There were significant differences between
the administration of morphine 2x10 mg and 2x30 mg (p <0.001). Side effects
were obtained after 2x30 mg morphine such as 33.3% complained of constipation,
drowsiness in 42.4%, and nausea in 12.1%. No patients experienced severe
respiratory depression.
Conclusion: There is dyspnea improvement after administration of sustainedrelease
morphine tablet 2x10 mg and better improvement with 2x30 mg. No severe side effects after administration of oral morphine., Background: Dyspnea is a major complaint in lung cancer. Opioids drugs such as
morphine is known to be used to reduce dyspnea. This study aims to determine
whether there is an improvement of dyspnea by titrating morphine sustained
release tablet 2x10 mg and 2x30 mg in lung cancer patient, and the side effects
that appear.
Methods: The study is a clinical trial with the subject of lung cancer patients by
comparing dyspnea before and after administration of 2x10 mg morphine tablets
for 2 days, followed by 2x30 mg for 2 days. The degree of dyspnea assessed using
the modified Borg's dyspnea scale and the Visual Analog Scale (VAS) for
dyspnea. Side effects are observed during administration of the drug.
Results: Thirty-three study participants with predominantly 27 men (81.8%) and
25 participants with adenocarcinoma (75.8%). There were improvements in
dyspnea after morphine 2x10 mg in 18 of the 33 participants (54.5%) with an
average improvements of Borg and VAS scores for 0.70 and 6.72 with p <0.001
compared to the initial score. After administration of morphine 2x30 mg
improvements in dyspnea were obtained in 26 of the 33 participants (78.8%) with
an average improvements of Borg and VAS scores for 1.64 and 16.06 with p
<0.001 compared to the initial score. There were significant differences between
the administration of morphine 2x10 mg and 2x30 mg (p <0.001). Side effects
were obtained after 2x30 mg morphine such as 33.3% complained of constipation,
drowsiness in 42.4%, and nausea in 12.1%. No patients experienced severe
respiratory depression.
Conclusion: There is dyspnea improvement after administration of sustainedrelease
morphine tablet 2x10 mg and better improvement with 2x30 mg. No severe side effects after administration of oral morphine.]"
